Filing Flows › Humacyte (HUMA) › Q1 2026 › vs Q1 2025
Humacyte (HUMA) Q1 2026 vs Q1 2025 (year over year)
Humacyte's revenue fell $22K (-4%) from $517K in Q1 2025 to $495K in Q1 2026. The biggest changes: Product and Service Other −$368K (-99%); Product +$346K (+235%).
Humacyte, Q1 2026: revenue $495K (-4% year over year), net loss $17.6M, operating cash flow −$25.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product | $493K | $147K | $346K | +235% |
| Product and Service Other | $2K | $370K | −$368K | -99% |
| Revenue | $495K | $517K | −$22K | -4% |
| Other income, net | $11.3M | $62.3M | −$51.0M | -82% |
| Net loss | $17.6M | −$39.1M | $56.8M | — |
| Costs & expenses | $29.4M | $62.8M | −$33.4M | -53% |
| Operating costs | $29.4M | $23.7M | $5.7M | +24% |
| Cost of revenue | $2.0M | $147K | $1.9M | 14× |
| Research & development | $19.5M | $15.4M | $4.0M | +26% |
| Operating cash sources | $29.6M | $32.4M | −$2.8M | -9% |
| Depreciation | $1.3M | $1.3M | $34K | +3% |
| Share-based compensation | $3.2M | $2.5M | $683K | +27% |
| Cash used in operations | $25.1M | $28.6M | −$3.5M | -12% |
| Net loss absorbed | $17.6M | −$39.1M | $56.8M | — |
| Working capital & other | $12.0M | $71.5M | −$59.5M | -83% |
Questions
How much did Humacyte's revenue grow year over year in Q1 2026?
Humacyte's revenue fell $22K (-4%) from $517K in Q1 2025 to $495K in Q1 2026.
What drove Humacyte's revenue change in Q1 2026?
Product and Service Other −$368K (-99%); Product +$346K (+235%).